STOCK TITAN

Longeveron Inc SEC Filings

LGVN NASDAQ

Welcome to our dedicated page for Longeveron SEC filings (Ticker: LGVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Struggling to decode the biotech jargon buried in Longeveron’s SEC documents? Clinical-stage companies like Longeveron Inc pack trial data, FDA designations, and manufacturing risks into hundreds of pages, making it hard to spot what moves the stock.

Our platform solves that problem. Stock Titan delivers AI-powered summaries that turn the Longeveron annual report 10-K simplified, each Longeveron quarterly earnings report 10-Q filing, and every Longeveron 8-K material events explained into plain-English insights. Need real-time alerts? We stream Longeveron Form 4 insider transactions real-time so you instantly track Longeveron executive stock transactions Form 4 and monitor sentiment inside the boardroom.

Here’s how investors use it:

  • Compare R&D spend and cash runway across quarters with our Longeveron earnings report filing analysis.
  • Spot shelf registrations or trial read-outs the moment they hit EDGAR via curated 8-K summaries.
  • Review compensation grids in the latest Longeveron proxy statement executive compensation without scrolling through tables.
  • Audit insider confidence with detailed logs of Longeveron insider trading Form 4 transactions.

Whether you’re understanding Longeveron SEC documents with AI for the first time or need a deeper dive into pipeline risk factors, Stock Titan covers every form—10-K, 10-Q, 8-K, S-1, S-3, and more—with real-time feeds and expert context. Longeveron SEC filings explained simply means you can focus on investment decisions, not document hunting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Longeveron General Counsel and Secretary Paul T. Lehr reported significant insider transactions on June 23, 2025. The transactions involved:

  • Acquisition of 163,043 restricted stock units (RSUs) that fully vested on the grant date
  • Disposition of 64,158 shares at $1.15 per share through share withholding for tax obligations
  • Following these transactions, Lehr holds 255,635 shares directly, including RSUs subject to future vesting

The Form 4 filing demonstrates substantial equity-based compensation for a key executive officer, with immediate vesting of the new RSU grant. The share withholding for tax purposes is a common practice for executive equity compensation arrangements. This insider activity provides insights into Longeveron's executive compensation structure and retention strategies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Longeveron Inc. (LGVN) has filed a Form S-8 to register an additional 4,000,000 shares of Class A Common Stock for issuance under its Third Amended and Restated 2021 Incentive Award Plan. The new shares, which were approved by shareholders on 13 June 2025, are in addition to 1,657,441 shares previously registered on three earlier S-8 filings (February 2021, June 2023 and July 2024, all share counts adjusted for a 26 March 2024 reverse split). Accordingly, the plan now has 5,657,441 registered shares available for equity-based compensation.

The filing is submitted under General Instruction E, thereby incorporating by reference all prior S-8 registration statements and the company’s periodic reports, including the Form 10-K for the fiscal year ended 31 Dec 2024 and all Forms 10-Q/8-K filed thereafter. Buchanan Ingersoll & Rooney PC rendered the legality opinion (its attorneys collectively own 2,000 LGVN shares), and Marcum LLP provided the auditor’s consent.

Key implications for investors:

  • Equity dilution risk: The 4 million newly registered shares will expand the incentive pool, increasing the potential supply of freely tradable shares as awards vest and are exercised.
  • Talent retention & alignment: A larger equity pool can strengthen management and employee retention incentives by allowing additional grants.
  • Shareholder oversight: Because the share increase required shareholder approval, governance processes were followed; LGVN remains a smaller reporting company and emerging growth company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
registration

FAQ

What is the current stock price of Longeveron (LGVN)?

The current stock price of Longeveron (LGVN) is $0.76 as of August 15, 2025.

What is the market cap of Longeveron (LGVN)?

The market cap of Longeveron (LGVN) is approximately 13.1M.
Longeveron Inc

NASDAQ:LGVN

LGVN Rankings

LGVN Stock Data

13.05M
11.86M
12.3%
8.59%
3.97%
Biotechnology
Pharmaceutical Preparations
Link
United States
MIAMI